A new research pipeline uses competing AI models as automated literature reviewers — and the output is a vetted engineering checklist, not a clinical product.
Researchers describe a workflow in which four independent commercial LLM families each read documentation from 68 public physiological datasets, all screened for commercial-use compatibility. The models generated 695 candidate rule markers; deduplication trimmed that to 649, and a threshold-bounds audit flagged 51 entries for clamping or human review. Cross-corpus consolidation left 436 unique rule shapes. From those, 94 were tagged as ready-to-build detector components — cleared because they matched available hardware channels and required no multi-night per-patient personalization.
The approach matters because physiological datasets are a mess: different sensors, sampling rates, clinical endpoints, and label schemes make direct comparison hard. Using multiple LLM families as independent analysts introduces a form of structured disagreement — where models diverge, a curator gets flagged, which is a more honest audit trail than a single-model sweep would produce. That auditable cascade, with CI checks baked in, is closer to how safety-critical engineering should handle literature-derived evidence.
The paper is careful to say this pipeline produces no validated clinical detector — just a prioritized build list. That disclaimer is doing a lot of work in a field where "AI-powered health monitoring" is often marketing before it is medicine.